Understanding Anti Il 13 Phase 2 Trial For Eosinophilic Esophagitis
Exploring Anti Il 13 Phase 2 Trial For Eosinophilic Esophagitis reveals several interesting facts. Marc E. Rothenberg, MD, PhD speaks about recent news for
Key Takeaways about Anti Il 13 Phase 2 Trial For Eosinophilic Esophagitis
- Marc Rothenberg, MD, PhD discusses the results of a single-site, randomized, double-blind, placebo-controlled,
- Marc Rothenberg MD, PhD, Professor and Director of Allergy/Immunology, Cincinnati Children's Hospital.
- Ariel Munitz from Tel-Aviv University presents their Original Article published in Allergy: Avlas, S., Shani, G., Rhone, N., et al.
- EoE
- ... Therapeutics Results from
Detailed Analysis of Anti Il 13 Phase 2 Trial For Eosinophilic Esophagitis
... '1104, in a Emerging therapies for Eosinophilic esophagitis
Jonathan Rigby, MD, President, Group CEO, and Board Member at Revolo Biotherapeutics, gives an overview of
Stay tuned for more updates related to Anti Il 13 Phase 2 Trial For Eosinophilic Esophagitis.